CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 250 enrolled
Drug / intervention
Amoxicillin-Clavulanate and/or Ceftriaxone +2 moredrug
Likely dose
Amoxicillin-Clavulanate and/or Ceftriaxone 6.4 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02567825
NCT02567825N/ACompleted

Efficacy of Tympanostomy Tubes for Children With Recurrent Acute Otitis Media

Alejandro Hoberman·interventional·Posted Oct 5, 2015·Updated Jul 15, 2022

In Brief

A clinical study evaluating Tympanostomy tube placement, Amoxicillin-Clavulanate and/or Ceftriaxone, and 1 other intervention for Acute Otitis Media. Completed, enrolled 250 participants across 2 sites.

Detailed Summary

To determine whether tympanostomy tube placement (TTP) compared with nonsurgical management will meaningfully improve children's acute otitis media (AOM) experience over the succeeding 2 years.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 5, 2015
Enrollment StartNov 1, 2015
Primary CompletionMar 1, 2020
Study CompletionFeb 1, 2021
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 10.7 years ago

Interventions

Tympanostomy tube placementdevice

As per routine care, tympanostomy tubes will be inserted under general anesthesia, using a small radial incision in the anteroinferior portion of the tympanic membrane; a Teflon® Armstrong-type tympanostomy tube will be used.

Amoxicillin-Clavulanate and/or Ceftriaxonedrug

Children randomized to nonsurgical management will receive stepwise therapy with amoxicillin-clavulanate (90/6.4 mg/kg in two divided doses for 10 days), and in the event of inadequate response, ceftriaxone (75 mg/kg intramuscularly, repeated in 48 hours), as recommended in the American Academy of Pediatrics guidelines.

Ofloxacin Oticdrug

Participants randomized to receive tympanostomy tubes will also be followed overtime for recurrences of AOM and treated with topical ofloxacin (Floxin® 0.3%, 5 mL) 5 drops into the affected ear twice daily for 10 days. Persistence of otorrhea after 7 days of treatment will be considered inadequate response, and children so affected will be prescribed empiric amoxicillin-clavulanate (90/6.4 mg/kg/day in two divided doses) followed by culture-directed therapy 48 hours later.